Toronto Public Health Vaccine Dashboard

Toronto Stronger TOgether initiative

eAwaz Medicine

Toronto – Mayor John Tory launched nominations for the Toronto Community Champion Award, as part of the Stronger TOgether initiative funded in part by the Government of Canada, to recognize organizations that provided exceptional support for Torontonians during the pandemic. The awards are now open for residents to nominate organizations that provided vital support to individuals and communities throughout the COVID-19 …

JCOVDEN™ Covid 19 Vaccine Ad26.COV2 S recombinant

Janssen’s COVID-19 Vaccine Global Information

eAwaz Medicine

London – The authorization or approval status of Janssen’s Covid-19 vaccine varies by country. Unless approved or licensed by the relevant health authority, the product is investigational and its safety and efficacy have not been established. JCOVDEN™ (Covid-19 Vaccine (Ad26.COV2-S [recombinant])) is indicated for active immunization for the prevention of coronavirus disease-2019 (Covid-19) caused by SARS-CoV-2 virus in individuals 18 …

96788

Novavax Nuvaxovid COVID-19 vaccine

eAwaz Medicine

All COVID-19 vaccines authorized in Canada are proven safe, effective and of high quality. Name: Novavax Nuvaxovid® COVID-19 vaccine Manufacturer: Novavax Inc. Type: protein-based vaccine Status: Approved by Health Canada Approved for: Age 18 and older How it’s given: Injection in muscle (usually the upper arm) Number of doses: 2 doses Who the vaccine is approved for The vaccine is approved for people who are 18 years of …

Pfizers Bivalent Vaccine Candidate

Pfizer’s Bivalent Vaccine Candidate

eAwaz Medicine

Kirkland – Pfizer Canada and BioNTech recently filed a New Drug Submission (NDS) with Health Canada for an Omicron-adapted bivalent COVID-19 vaccine candidate, based on the BA.1 sub-lineage, to be administered as a booster dose in individuals 12 years of age and older. This application follows guidance from Health Canada to work towards the introduction of an Omicron-adapted bivalent vaccine …

COMIRNATY

Pfizer presents Adapted Bivalent Vaccine Candidate for Omicron BA.1

eAwaz Medicine

Kirkland – Pfizer Canada and BioNTech filed a New Drug Submission (NDS) with Health Canada for an Omicron-adapted bivalent COVID-19 vaccine candidate, based on the BA.1 sub-lineage, to be administered as a booster dose in individuals 12 years of age and older. This application follows guidance from Health Canada to work towards the introduction of an Omicron-adapted bivalent vaccine candidate …

Moderna Spikevax

Health Canada on Moderna’s Spikevax Covid-19 vaccine

eAwaz Medicine

Ottawa – The vaccine is approved for people who are 6 years of age and older. Its safety and effectiveness in people younger than 6 years of age have not yet been established. Effectiveness Clinical trials showed that beginning 2 weeks after the second dose, the Moderna Spikevax® COVID vaccine was: 94.1% effective in protecting trial participants aged 18 and above …

vaccination clinic

Toronto partners enhance Covid-19 vax opportunities 

eAwaz Medicine

Toronto – Toronto Public Health (TPH) continues to work hard with Team Toronto health and community partners to offer hyper-local COVID-19 vaccine opportunities to residents. TPH and Team Toronto partners have added eight clinics in the northwest part of the city for the month of June to augment vaccination opportunities for residents who live, work and play in these neighbourhoods. …

AstraZeneca

AstraZeneca Vaxzevria Covid-19 vaccine

eAwaz Medicine

Ottawa – All COVID-19 vaccines authorized in Canada are proven safe, effective and of high quality. Name: AstraZeneca Vaxzevria® COVID-19 vaccine Manufacturer: AstraZeneca Canada Inc and Verity/SII (COVISHIELD) Type: Viral vector-based Status: Approved by Health Canada Approved for: Age 18 and older How it’s given: Injection in muscle (usually the upper arm) Number of doses: 2 doses Note: The COVISHIELD version of this vaccine provided a temporary supply …

Vaxzevria

Vaxzevria approved in the EU as 3rd dose booster against covid

eAwaz Medicine

London – AstraZeneca’s COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), has been granted approval in the European Union (EU) by the European Medicine Agency (EMA) as a third dose booster in adults. Healthcare professionals can now use Vaxzevria as a third dose booster in patients previously given a primary vaccine schedule of either Vaxzevria or an EU-approved mRNA COVID-19 vaccine. The authorisation is based on a review by …

Corbevax

Corbevax for 5-12 year age group

eAwaz Medicine

Mumbai – Expert panel of India’s central drug authority is recommending to grant emergency use authorisation for Biological E’s Covid-19 vaccine Corbevax for children in 5 to 12 years age group. the Indian government has sought more data from Bharat Biotech before granting approval for use of its Covid-19 vaccine, Covaxin, in children aged 5-12.